{
  "1TB.F": {
    "city": "Copenhagen",
    "country": "Denmark",
    "currency": "EUR",
    "exchange": "FRA",
    "industry": "Biotechnology",
    "long_name": "Orphazyme A/S",
    "market": "dr_market",
    "market_cap": "Small Cap",
    "sector": "Healthcare",
    "short_name": "ORPHAZYME A/S  DK 1",
    "state": null,
    "summary": "Orphazyme A/S, a biopharmaceutical company, develops therapies for the treatment of neurodegenerative orphan diseases. The company focuses on the amplification of heat-shock proteins to develop and commercialize therapeutics for diseases caused by protein misfolding and aggregation, and lysosomal dysfunction, including lysosomal storage and neuromuscular degenerative diseases. Its lead candidate is the Arimoclomol, which is in clinical development for four orphan diseases, including Niemann-Pick disease type C, Amyotrophic Lateral Sclerosis, Inclusion Body Myositis, and Gaucher disease. The company was incorporated in 2009 and is headquartered in Copenhagen, Denmark.",
    "website": "http://www.orphazyme.com",
    "zipcode": "2200"
  },
  "1TBD.F": {
    "city": "Copenhagen",
    "country": "Denmark",
    "currency": "EUR",
    "exchange": "FRA",
    "industry": "Biotechnology",
    "long_name": "Orphazyme A/S",
    "market": "dr_market",
    "market_cap": "Micro Cap",
    "sector": "Healthcare",
    "short_name": "ORPHAZYME A/S ADR/1 O.N.",
    "state": null,
    "summary": "Orphazyme A/S, a biopharmaceutical company, develops therapies for the treatment of neurodegenerative orphan diseases. The company focuses on the amplification of heat-shock proteins to develop and commercialize therapeutics for diseases caused by protein misfolding and aggregation, and lysosomal dysfunction, including lysosomal storage and neuromuscular degenerative diseases. Its lead candidate is the Arimoclomol, which is in clinical development for four orphan diseases, including Niemann-Pick disease type C, Amyotrophic Lateral Sclerosis, Inclusion Body Myositis, and Gaucher disease. The company was incorporated in 2009 and is headquartered in Copenhagen, Denmark.",
    "website": "http://www.orphazyme.com",
    "zipcode": "2200"
  },
  "30S.F": {
    "city": "Glostrup",
    "country": "Denmark",
    "currency": "EUR",
    "exchange": "FRA",
    "industry": "Biotechnology",
    "long_name": "Saniona AB (publ)",
    "market": "dr_market",
    "market_cap": "Micro Cap",
    "sector": "Healthcare",
    "short_name": "SANIONA AB (PUBL)",
    "state": null,
    "summary": "Saniona AB (publ), a research and development company, engages in the development of drugs for diseases of the central nervous system and eating disorders in Denmark. It has a portfolio of various drug candidates in pre-clinical and clinical stages. The company's products include Tesofensine, a triple monoamine reuptake inhibitor; Tesomet, a fix-dose combination of tesofensine and metoprolol that has completed the Phase 2 clinical trials for the treatment of prader-willi syndrome and hypothalamic obesity; and CAD-1883 for movement disorders. It is also developing SAN711 for rare neuropathic disorders, which is in Phase 1; SAN903 that is in preclinical stage for rare inflammatory/fibrotic disorders; and Boehringer Ingelheim program for schizophrenia. Saniona AB (publ) was founded in 2011 and is headquartered in Glostrup, Denmark.",
    "website": "http://www.saniona.com",
    "zipcode": "2600"
  },
  "5JD.F": {
    "city": "Horsholm",
    "country": "Denmark",
    "currency": "EUR",
    "exchange": "FRA",
    "industry": "Biotechnology",
    "long_name": "ExpreS2ion Biotech Holding AB (publ)",
    "market": "dr_market",
    "market_cap": "Micro Cap",
    "sector": "Healthcare",
    "short_name": "EXPRES2ION BIOTECH HLDG",
    "state": null,
    "summary": "ExpreS2ion Biotech Holding AB (publ), through its subsidiary, ExpreS2 ion Biotechnologies ApS, develops a platform technology that enables the production of complex proteins for new vaccines and diagnostics of malaria. The company develops ExpreS2 platform, an S2 cell that produce proteins. Its ExpreS2 kit include ExpreS2 plasmids, ExpreS2 cells, ExpreS2 transfection reagents, culture media for S2 cells, and plasmid maps and protocols for use. The company also offers ExpreS2 TR, a transfection reagent, which is formulated and optimized for insect cell transfection; placental malaria vaccine; and blood stage malaria vaccine. In addition, it provides upstream process development and a range of products and services related to ExpreS2 protein expression platform. ExpreS2ion has research collaboration with University of Bologna to test HER2-cVLP in state-of-the-art breast cancer mice models. ExpreS2ion Biotech Holding AB (publ) is based in Horsholm, Denmark.",
    "website": "http://www.expres2ionbio.com",
    "zipcode": "2970"
  },
  "8VY.F": {
    "city": "Copenhagen",
    "country": "Denmark",
    "currency": "EUR",
    "exchange": "FRA",
    "industry": "Biotechnology",
    "long_name": "Scandion Oncology A/S",
    "market": "dr_market",
    "market_cap": "Micro Cap",
    "sector": "Healthcare",
    "short_name": "SCANDION ONC.  DK-,0735",
    "state": null,
    "summary": "Scandion Oncology A/S, a biotechnology company, develops drugs for the treatment of chemotherapy resistance in cancer patients. Its products under development include SCO-101, which is in Phase II clinical trial for use in the treatment of breast and colorectal cancers; and SCO-201, a late pre-clinical stage product for use in the treatment of solid tumors. Scandion Oncology A/S has a collaboration agreement with Alligator Bioscience AB to explore combination therapies for chemotherapy and immunooncology. The company was founded in 2017 and is based in Copenhagen, Denmark.",
    "website": "http://www.scandiononcology.com",
    "zipcode": "2100"
  },
  "A71.F": {
    "city": "Hellerup",
    "country": "Denmark",
    "currency": "EUR",
    "exchange": "FRA",
    "industry": "Biotechnology",
    "long_name": "Ascendis Pharma A/S",
    "market": "dr_market",
    "market_cap": "Mid Cap",
    "sector": "Healthcare",
    "short_name": "ASCENDIS PH.SP.ADR 1 DK 1",
    "state": null,
    "summary": "Ascendis Pharma A/S, a biopharmaceutical company, develops therapeutics for unmet medical needs. The company develops TransCon growth hormone, which completed Phase III clinical trials for growth hormone deficiency. It also develops TransCon parathyroid hormone for adult hypoparathyroidism; and TransCon CNP for achondroplasia. In addition, the company develops preclinical studies in the field of oncology for potential product candidates and evaluate systemic and localized delivery systems using its TransCon technologies. The company was incorporated in 2006 and is headquartered in Hellerup, Denmark.",
    "website": "http://www.ascendispharma.com",
    "zipcode": "2900"
  },
  "AKABY": {
    "city": "Horsholm",
    "country": "Denmark",
    "currency": "USD",
    "exchange": "PNK",
    "industry": "Biotechnology",
    "long_name": "ALK-Abelló A/S",
    "market": "us_market",
    "market_cap": "Mid Cap",
    "sector": "Healthcare",
    "short_name": "ALK-ABELLO A/S",
    "state": null,
    "summary": "ALK-AbellÃ³ A/S operates as an allergy solutions company in Europe, North America, and internationally. The company offers allergy immunotherapy products in the form of injections, sublingual drops, and tablets for the treatment of various allergies, including house dust mite, grass, tree, ragweed, and Japanese cedar. Its products include GRAZAX, RAGWITEK, RAGWIZAX, MITICURE, ODACTRA, CEDARCURE, and ITULAZAX for the treatment of allergic rhinitis; and ACARIZAX for treating allergic rhinitis and allergic asthma. ALK-AbellÃ³ A/S was founded in 1923 and is headquartered in HÃ¸rsholm, Denmark.",
    "website": "http://www.alk.net",
    "zipcode": "2970"
  },
  "AKBLF": {
    "city": "Horsholm",
    "country": "Denmark",
    "currency": "USD",
    "exchange": "PNK",
    "industry": "Biotechnology",
    "long_name": "ALK-Abelló A/S",
    "market": "us_market",
    "market_cap": "Mid Cap",
    "sector": "Healthcare",
    "short_name": "ALK-ABELLO A/S",
    "state": null,
    "summary": "ALK-AbellÃ³ A/S operates as an allergy solutions company in Europe, North America, and internationally. The company offers allergy immunotherapy products in the form of injections, sublingual drops, and tablets for the treatment of various allergies, including house dust mite, grass, tree, ragweed, and Japanese cedar. Its products include GRAZAX, RAGWITEK, RAGWIZAX, MITICURE, ODACTRA, CEDARCURE, and ITULAZAX for the treatment of allergic rhinitis; and ACARIZAX for treating allergic rhinitis and allergic asthma. ALK-AbellÃ³ A/S was founded in 1923 and is headquartered in HÃ¸rsholm, Denmark.",
    "website": "http://www.alk.net",
    "zipcode": "2970"
  },
  "ALLR.ST": {
    "city": "Horsholm",
    "country": "Denmark",
    "currency": "SEK",
    "exchange": "STO",
    "industry": "Biotechnology",
    "long_name": "Allarity Therapeutics A/S",
    "market": "se_market",
    "market_cap": "Nano Cap",
    "sector": "Healthcare",
    "short_name": "Allarity Therapeutics A/S",
    "state": null,
    "summary": "Allarity Therapeutics A/S develops drugs for the treatment of cancer using drug-specific companion diagnostics. Its product pipeline includes stenoparib, a PARP inhibitor in Phase II clinical trials for the treatment of ovarian cancer, as well as in pre-clinical studies for the treatment of coronavirus; dovitinib, a pan-tyrosine kinase inhibitor in post-Phase III clinical trials for treatment renal cell carcinoma; and IXEMPRA, a microtublin inhibitor, which is in Phase II clinical for treatment of metastatic breast cancer. The company is also developing LiPlaCis, a liposomal formulation of cisplatin in Phase II clinical trials for breast and prostate cancer; 2X-111, a liposomal formulation of doxorubicin for the treatment of brain cancer; and Irofulven, a DNA damaging agent in Phase II clinical trials for prostate cancer. The company was formerly known as Oncology Venture A/S and changed its name to Allarity Therapeutics A/S in October 2020. Allarity Therapeutics A/S was founded in 2004 and is headquartered in HÃ¸rsholm, Denmark.",
    "website": "http://www.allarity.com",
    "zipcode": "2970"
  },
  "ASND": {
    "city": "Hellerup",
    "country": "Denmark",
    "currency": "USD",
    "exchange": "NMS",
    "industry": "Biotechnology",
    "long_name": "Ascendis Pharma A/S",
    "market": "us_market",
    "market_cap": "Mid Cap",
    "sector": "Healthcare",
    "short_name": "Ascendis Pharma A/S",
    "state": null,
    "summary": "Ascendis Pharma A/S, a biopharmaceutical company, develops therapeutics for unmet medical needs. The company develops TransCon growth hormone, which completed Phase III clinical trials for growth hormone deficiency. It also develops TransCon parathyroid hormone for adult hypoparathyroidism; and TransCon CNP for achondroplasia. In addition, the company develops preclinical studies in the field of oncology for potential product candidates and evaluate systemic and localized delivery systems using its TransCon technologies. The company was incorporated in 2006 and is headquartered in Hellerup, Denmark.",
    "website": "http://www.ascendispharma.com",
    "zipcode": "2900"
  },
  "BAVA.CO": {
    "city": "Hellerup",
    "country": "Denmark",
    "currency": "DKK",
    "exchange": "CPH",
    "industry": "Biotechnology",
    "long_name": "Bavarian Nordic A/S",
    "market": "dk_market",
    "market_cap": "Mid Cap",
    "sector": "Healthcare",
    "short_name": "Bavarian Nordic A/S",
    "state": null,
    "summary": "Bavarian Nordic A/S develops, manufactures, and commercializes life-saving vaccines. The company offers non-replicating smallpox vaccines under the IMVAMUNE, IMVANEX, and JYNNEOS names; monkeypox under the JYNNEOS name; rabies vaccine for human use under the Rabipur/RabAvert name; tick-borne encephalitis vaccine under the Encepur name; and Ebola vaccine under the MVABEA name. It is also developing MVA-BN (freeze-dried) that is in Phase III clinical trials for the treatment of smallpox; MVA-BN RSV, which is in Phase II clinical trials for the treatment of respiratory syncytial virus; ABNCoV2 that is in Phase I/II clinical trial for the treatment of SARS-CoV-2; TAEK-VAC, which is in Phase I/II clinical trial for treatment of advanced HER2- and brachyury-expressing cancers; and MVA-BN WEV that is in Phase I clinical trial for treating Equine encephalitis.It has license and collaboration agreement with AdaptVac; and license agreements with National Cancer Institute and Public Health Service. The company operates in the United States, Germany, the Netherlands, Sweden, Switzerland, Austria, the United Kingdom, Japan, Canada, and internationally. Bavarian Nordic A/S was incorporated in 1992 and is based in Hellerup, Denmark.",
    "website": "http://www.bavarian-nordic.com",
    "zipcode": "2900"
  },
  "BV3.F": {
    "city": "Hellerup",
    "country": "Denmark",
    "currency": "EUR",
    "exchange": "FRA",
    "industry": "Biotechnology",
    "long_name": "Bavarian Nordic A/S",
    "market": "dr_market",
    "market_cap": "Mid Cap",
    "sector": "Healthcare",
    "short_name": "BAVARIAN NOR  NAM.  DK 10",
    "state": null,
    "summary": "Bavarian Nordic A/S develops, manufactures, and commercializes life-saving vaccines. The company offers non-replicating smallpox vaccines under the IMVAMUNE, IMVANEX, and JYNNEOS names; monkeypox under the JYNNEOS name; rabies vaccine for human use under the Rabipur/RabAvert name; tick-borne encephalitis vaccine under the Encepur name; and Ebola vaccine under the MVABEA name. It is also developing MVA-BN (freeze-dried) that is in Phase III clinical trials for the treatment of smallpox; MVA-BN RSV, which is in Phase II clinical trials for the treatment of respiratory syncytial virus; ABNCoV2 that is in Phase I/II clinical trial for the treatment of SARS-CoV-2; TAEK-VAC, which is in Phase I/II clinical trial for treatment of advanced HER2- and brachyury-expressing cancers; and MVA-BN WEV that is in Phase I clinical trial for treating Equine encephalitis.It has license and collaboration agreement with AdaptVac; and license agreements with National Cancer Institute and Public Health Service. The company operates in the United States, Germany, the Netherlands, Sweden, Switzerland, Austria, the United Kingdom, Japan, Canada, and internationally. Bavarian Nordic A/S was incorporated in 1992 and is based in Hellerup, Denmark.",
    "website": "http://www.bavarian-nordic.com",
    "zipcode": "2900"
  },
  "BVNKF": {
    "city": "Hellerup",
    "country": "Denmark",
    "currency": "USD",
    "exchange": "PNK",
    "industry": "Biotechnology",
    "long_name": "Bavarian Nordic A/S",
    "market": "us_market",
    "market_cap": "Mid Cap",
    "sector": "Healthcare",
    "short_name": "BAVARIAN NORDIC",
    "state": null,
    "summary": "Bavarian Nordic A/S develops, manufactures, and commercializes life-saving vaccines. The company offers non-replicating smallpox vaccines under the IMVAMUNE, IMVANEX, and JYNNEOS names; monkeypox under the JYNNEOS name; rabies vaccine for human use under the Rabipur/RabAvert name; tick-borne encephalitis vaccine under the Encepur name; and Ebola vaccine under the MVABEA name. It is also developing MVA-BN (freeze-dried) that is in Phase III clinical trials for the treatment of smallpox; MVA-BN RSV, which is in Phase II clinical trials for the treatment of respiratory syncytial virus; ABNCoV2 that is in Phase I/II clinical trial for the treatment of SARS-CoV-2; TAEK-VAC, which is in Phase I/II clinical trial for treatment of advanced HER2- and brachyury-expressing cancers; and MVA-BN WEV that is in Phase I clinical trial for treating Equine encephalitis.It has license and collaboration agreement with AdaptVac; and license agreements with National Cancer Institute and Public Health Service. The company operates in the United States, Germany, the Netherlands, Sweden, Switzerland, Austria, the United Kingdom, Japan, Canada, and internationally. Bavarian Nordic A/S was incorporated in 1992 and is based in Hellerup, Denmark.",
    "website": "http://www.bavarian-nordic.com",
    "zipcode": "2900"
  },
  "BVNRY": {
    "city": "Hellerup",
    "country": "Denmark",
    "currency": "USD",
    "exchange": "PNK",
    "industry": "Biotechnology",
    "long_name": "Bavarian Nordic A/S",
    "market": "us_market",
    "market_cap": "Mid Cap",
    "sector": "Healthcare",
    "short_name": "BAVARIAN NORDIC",
    "state": null,
    "summary": "Bavarian Nordic A/S develops, manufactures, and commercializes life-saving vaccines. The company offers non-replicating smallpox vaccines under the IMVAMUNE, IMVANEX, and JYNNEOS names; monkeypox under the JYNNEOS name; rabies vaccine for human use under the Rabipur/RabAvert name; tick-borne encephalitis vaccine under the Encepur name; and Ebola vaccine under the MVABEA name. It is also developing MVA-BN (freeze-dried) that is in Phase III clinical trials for the treatment of smallpox; MVA-BN RSV, which is in Phase II clinical trials for the treatment of respiratory syncytial virus; ABNCoV2 that is in Phase I/II clinical trial for the treatment of SARS-CoV-2; TAEK-VAC, which is in Phase I/II clinical trial for treatment of advanced HER2- and brachyury-expressing cancers; and MVA-BN WEV that is in Phase I clinical trial for treating Equine encephalitis.It has license and collaboration agreement with AdaptVac; and license agreements with National Cancer Institute and Public Health Service. The company operates in the United States, Germany, the Netherlands, Sweden, Switzerland, Austria, the United Kingdom, Japan, Canada, and internationally. Bavarian Nordic A/S was incorporated in 1992 and is based in Hellerup, Denmark.",
    "website": "http://www.bavarian-nordic.com",
    "zipcode": "2900"
  },
  "EVAX": {
    "city": "Hoersholm",
    "country": "Denmark",
    "currency": "USD",
    "exchange": "NMS",
    "industry": "Biotechnology",
    "long_name": "Evaxion Biotech A/S",
    "market": "us_market",
    "market_cap": "Micro Cap",
    "sector": "Healthcare",
    "short_name": "Evaxion Biotech A/S",
    "state": null,
    "summary": "Evaxion Biotech A/S, a clinical-stage artificial intelligence-immunology platform company, identifies and develops novel immunotherapies for the treatment of various cancers, bacterial diseases, and viral infections. The company develops therapies using PIONEER, an immuno-oncology platform; EDEN, a bacterial disease platform; and RAVENTM, a viral disease platform. It develops EVX-01, a novel liposomal, peptide-based cancer immunotherapy that is in clinical Phase I/IIa trial for indications, such as metastatic and/or unresectable melanoma, non-small cell lung cancer, and bladder cancer; EVX-02, a novel, DNA-based cancer immunotherapy that is in Phase I/IIa trial designed to induce a therapeutic immune response in the adjuvant setting in patients with resected melanoma; and EVX-03, a DNA-based neoepitope immunotherapy, which is in late pre-clinical development for the treatment of various cancers, as well as EVX-B1, a multi-component subunit vaccine, which is in pre-clinical development for the prevention of S. aureus induced skin and soft tissue infections in patients undergoing hernia surgery. The company has collaboration agreements with National Center for Cancer Immune Therapy (CCIT-DK) at Herlev Hospital, Department of Health Technology at Danish Technical University, Center for Genomic Medicine at University Hospital Copenhagen, and the Center for Vaccine Research at SSI for the development and Phase 1/2a clinical trial of its EVX-01 product candidate. Evaxion Biotech A/S was incorporated in 2008 and is headquartered in Hoersholm, Denmark.",
    "website": "http://www.evaxion-biotech.com",
    "zipcode": "2970"
  },
  "EXPRS2.ST": {
    "city": "Horsholm",
    "country": "Denmark",
    "currency": "SEK",
    "exchange": "STO",
    "industry": "Biotechnology",
    "long_name": "ExpreS2ion Biotech Holding AB (publ)",
    "market": "se_market",
    "market_cap": "Micro Cap",
    "sector": "Healthcare",
    "short_name": "ExpreS2ion Biotech Holding AB",
    "state": null,
    "summary": "ExpreS2ion Biotech Holding AB (publ), through its subsidiary, ExpreS2 ion Biotechnologies ApS, develops a platform technology that enables the production of complex proteins for new vaccines and diagnostics of malaria. The company develops ExpreS2 platform, an S2 cell that produce proteins. Its ExpreS2 kit include ExpreS2 plasmids, ExpreS2 cells, ExpreS2 transfection reagents, culture media for S2 cells, and plasmid maps and protocols for use. The company also offers ExpreS2 TR, a transfection reagent, which is formulated and optimized for insect cell transfection; placental malaria vaccine; and blood stage malaria vaccine. In addition, it provides upstream process development and a range of products and services related to ExpreS2 protein expression platform. ExpreS2ion has research collaboration with University of Bologna to test HER2-cVLP in state-of-the-art breast cancer mice models. ExpreS2ion Biotech Holding AB (publ) is based in Horsholm, Denmark.",
    "website": "http://www.expres2ionbio.com",
    "zipcode": "2970"
  },
  "FWP": {
    "city": "Copenhagen",
    "country": "Denmark",
    "currency": "USD",
    "exchange": "NMS",
    "industry": "Biotechnology",
    "long_name": "Forward Pharma A/S",
    "market": "us_market",
    "market_cap": "Micro Cap",
    "sector": "Healthcare",
    "short_name": "Forward Pharma A/S",
    "state": null,
    "summary": "Forward Pharma A/S does not have significant operations. Previously, it operated as a biopharmaceutical company that focused on developing proprietary formulation of dimethyl fumarate for the treatment of inflammatory and neurological indications. The company was incorporated in 2005 and is headquartered in Copenhagen, Denmark.",
    "website": "http://www.forward-pharma.com",
    "zipcode": "1100"
  },
  "GLTO": {
    "city": "Copenhagen",
    "country": "Denmark",
    "currency": "USD",
    "exchange": "NMS",
    "industry": "Biotechnology",
    "long_name": "Galecto, Inc.",
    "market": "us_market",
    "market_cap": "Micro Cap",
    "sector": "Healthcare",
    "short_name": "Galecto, Inc.",
    "state": null,
    "summary": "Galecto, Inc., a clinical-stage biotechnology company, develops molecules for the treatment of fibrosis, cancer, inflammation, and other related diseases. The company's lead product candidate is GB0139, an inhaled inhibitor of galectin-3 that is in Phase IIb clinical trial for the treatment of severe fibrotic lung diseases, such as idiopathic pulmonary fibrosis, a life-threatening progressive fibrotic disease of the lung. Its products also comprise GB2064, which is in Phase I/IIa for the treatment of myelofibrosis; and GB1211, a selective oral galectin-3 inhibitor that is in Phase I/IIa for the treatment of cancer and fibrosis. Galecto, Inc. was founded in 2011 and is headquartered in Copenhagen, Denmark.",
    "website": "http://galecto.com",
    "zipcode": "2200"
  },
  "GMAB": {
    "city": "Copenhagen",
    "country": "Denmark",
    "currency": "USD",
    "exchange": "NMS",
    "industry": "Biotechnology",
    "long_name": "Genmab A/S",
    "market": "us_market",
    "market_cap": "Large Cap",
    "sector": "Healthcare",
    "short_name": "Genmab A/S",
    "state": null,
    "summary": "Genmab A/S, a biotechnology company, develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; ofatumumab, a human monoclonal antibody to treat chronic lymphocytic leukemia (CLL) and multiple sclerosis; and Arzerra for treating CLL. Its products under development include daratumumab to treat MM, non-MM blood cancers, and AL amyloidosis; tisotumab vedotin for treating cervical, ovarian, and solid cancers; HuMax-IL8 for treating advanced cancers; HexaBody-DR5/DR5, DuoBody-CD3x5T4, JNJ-63898081, JNJ-70218902, DuoBody-PD-L1x4-1BB, and DuoBody-CD40x4-1BB for treating solid tumors; and DuoBody-CD3xCD20 and DuoHexaBody-CD37 for treating hematological malignancies. The company's products under development also comprise Camidanlumab tesirine to treat hodgkin lymphoma and solid tumors; HuMax-IL8 for treating advanced cancers; JNJ-61186372 for the treatment of non-small-cell lung cancer; JNJ-63709178 and JNJ-67571244 to treat acute myeloid leukemia; JNJ-64007957 and JNJ-64407564 to treat MM; PRV-015 for treating celiac disease; Mim8 for treating haemophilia A; and Lu AF82422 for treating Parkinson's disease. In addition, it has approximately 20 active pre-clinical programs. The company has a commercial license and collaboration agreement with Seagen Inc. to co-develop tisotumab vedotin. It also has a collaboration agreement with Immatics Biotechnologies GmbH to research and develop next-generation bispecific immunotherapies for treating multiple cancer indications; CureVac AG for the research and development of differentiated mRNA-based antibody products; AbbVie for the development of epcoritamab; and BioNTech, Janssen, Novo Nordisk A/S, and BliNK Biomedical SAS. Genmab A/S was founded in 1999 and is headquartered in Copenhagen, Denmark.",
    "website": "http://www.genmab.com",
    "zipcode": "1560"
  },
  "GMAB.CO": {
    "city": "Copenhagen",
    "country": "Denmark",
    "currency": "DKK",
    "exchange": "CPH",
    "industry": "Biotechnology",
    "long_name": "Genmab A/S",
    "market": "dk_market",
    "market_cap": "Large Cap",
    "sector": "Healthcare",
    "short_name": "Genmab A/S",
    "state": null,
    "summary": "Genmab A/S, a biotechnology company, develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; ofatumumab, a human monoclonal antibody to treat chronic lymphocytic leukemia (CLL) and multiple sclerosis; and Arzerra for treating CLL. Its products under development include daratumumab to treat MM, non-MM blood cancers, and AL amyloidosis; tisotumab vedotin for treating cervical, ovarian, and solid cancers; HuMax-IL8 for treating advanced cancers; HexaBody-DR5/DR5, DuoBody-CD3x5T4, JNJ-63898081, JNJ-70218902, DuoBody-PD-L1x4-1BB, and DuoBody-CD40x4-1BB for treating solid tumors; and DuoBody-CD3xCD20 and DuoHexaBody-CD37 for treating hematological malignancies. The company's products under development also comprise Camidanlumab tesirine to treat hodgkin lymphoma and solid tumors; HuMax-IL8 for treating advanced cancers; JNJ-61186372 for the treatment of non-small-cell lung cancer; JNJ-63709178 and JNJ-67571244 to treat acute myeloid leukemia; JNJ-64007957 and JNJ-64407564 to treat MM; PRV-015 for treating celiac disease; Mim8 for treating haemophilia A; and Lu AF82422 for treating Parkinson's disease. In addition, it has approximately 20 active pre-clinical programs. The company has a commercial license and collaboration agreement with Seagen Inc. to co-develop tisotumab vedotin. It also has a collaboration agreement with Immatics Biotechnologies GmbH to research and develop next-generation bispecific immunotherapies for treating multiple cancer indications; CureVac AG for the research and development of differentiated mRNA-based antibody products; AbbVie for the development of epcoritamab; and BioNTech, Janssen, Novo Nordisk A/S, and BliNK Biomedical SAS. Genmab A/S was founded in 1999 and is headquartered in Copenhagen, Denmark.",
    "website": "http://www.genmab.com",
    "zipcode": "1560"
  },
  "GMAB.VI": {
    "city": "Copenhagen",
    "country": "Denmark",
    "currency": "EUR",
    "exchange": "VIE",
    "industry": "Biotechnology",
    "long_name": "Genmab A/S",
    "market": "at_market",
    "market_cap": "Large Cap",
    "sector": "Healthcare",
    "short_name": "GENMAB AS",
    "state": null,
    "summary": "Genmab A/S, a biotechnology company, develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; ofatumumab, a human monoclonal antibody to treat chronic lymphocytic leukemia (CLL) and multiple sclerosis; and Arzerra for treating CLL. Its products under development include daratumumab to treat MM, non-MM blood cancers, and AL amyloidosis; tisotumab vedotin for treating cervical, ovarian, and solid cancers; HuMax-IL8 for treating advanced cancers; HexaBody-DR5/DR5, DuoBody-CD3x5T4, JNJ-63898081, JNJ-70218902, DuoBody-PD-L1x4-1BB, and DuoBody-CD40x4-1BB for treating solid tumors; and DuoBody-CD3xCD20 and DuoHexaBody-CD37 for treating hematological malignancies. The company's products under development also comprise Camidanlumab tesirine to treat hodgkin lymphoma and solid tumors; HuMax-IL8 for treating advanced cancers; JNJ-61186372 for the treatment of non-small-cell lung cancer; JNJ-63709178 and JNJ-67571244 to treat acute myeloid leukemia; JNJ-64007957 and JNJ-64407564 to treat MM; PRV-015 for treating celiac disease; Mim8 for treating haemophilia A; and Lu AF82422 for treating Parkinson's disease. In addition, it has approximately 20 active pre-clinical programs. The company has a commercial license and collaboration agreement with Seagen Inc. to co-develop tisotumab vedotin. It also has a collaboration agreement with Immatics Biotechnologies GmbH to research and develop next-generation bispecific immunotherapies for treating multiple cancer indications; CureVac AG for the research and development of differentiated mRNA-based antibody products; AbbVie for the development of epcoritamab; and BioNTech, Janssen, Novo Nordisk A/S, and BliNK Biomedical SAS. Genmab A/S was founded in 1999 and is headquartered in Copenhagen, Denmark.",
    "website": "http://www.genmab.com",
    "zipcode": "1560"
  },
  "GNMSF": {
    "city": "Copenhagen",
    "country": "Denmark",
    "currency": "USD",
    "exchange": "PNK",
    "industry": "Biotechnology",
    "long_name": "Genmab A/S",
    "market": "us_market",
    "market_cap": "Large Cap",
    "sector": "Healthcare",
    "short_name": "GENMAB AS",
    "state": null,
    "summary": "Genmab A/S, a biotechnology company, develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; ofatumumab, a human monoclonal antibody to treat chronic lymphocytic leukemia (CLL) and multiple sclerosis; and Arzerra for treating CLL. Its products under development include daratumumab to treat MM, non-MM blood cancers, and AL amyloidosis; tisotumab vedotin for treating cervical, ovarian, and solid cancers; HuMax-IL8 for treating advanced cancers; HexaBody-DR5/DR5, DuoBody-CD3x5T4, JNJ-63898081, JNJ-70218902, DuoBody-PD-L1x4-1BB, and DuoBody-CD40x4-1BB for treating solid tumors; and DuoBody-CD3xCD20 and DuoHexaBody-CD37 for treating hematological malignancies. The company's products under development also comprise Camidanlumab tesirine to treat hodgkin lymphoma and solid tumors; HuMax-IL8 for treating advanced cancers; JNJ-61186372 for the treatment of non-small-cell lung cancer; JNJ-63709178 and JNJ-67571244 to treat acute myeloid leukemia; JNJ-64007957 and JNJ-64407564 to treat MM; PRV-015 for treating celiac disease; Mim8 for treating haemophilia A; and Lu AF82422 for treating Parkinson's disease. In addition, it has approximately 20 active pre-clinical programs. The company has a commercial license and collaboration agreement with Seagen Inc. to co-develop tisotumab vedotin. It also has a collaboration agreement with Immatics Biotechnologies GmbH to research and develop next-generation bispecific immunotherapies for treating multiple cancer indications; CureVac AG for the research and development of differentiated mRNA-based antibody products; AbbVie for the development of epcoritamab; and BioNTech, Janssen, Novo Nordisk A/S, and BliNK Biomedical SAS. Genmab A/S was founded in 1999 and is headquartered in Copenhagen, Denmark.",
    "website": "http://www.genmab.com",
    "zipcode": "1560"
  },
  "NNOR.VI": {
    "city": "Bagsvaerd",
    "country": "Denmark",
    "currency": "EUR",
    "exchange": "VIE",
    "industry": "Biotechnology",
    "long_name": "Novo Nordisk A/S",
    "market": "at_market",
    "market_cap": "Large Cap",
    "sector": "Healthcare",
    "short_name": "NOVO-NORDISK AS",
    "state": null,
    "summary": "Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Lund University to develop treatment for Parkinson's diseases; and bluebird bio, Inc. to develop genome editing treatments for children and adult patients. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.",
    "website": "http://www.novonordisk.com",
    "zipcode": "2880"
  },
  "NONOF": {
    "city": "Bagsvaerd",
    "country": "Denmark",
    "currency": "USD",
    "exchange": "PNK",
    "industry": "Biotechnology",
    "long_name": "Novo Nordisk A/S",
    "market": "us_market",
    "market_cap": "Mega Cap",
    "sector": "Healthcare",
    "short_name": "NOVO NORDISK A/S",
    "state": null,
    "summary": "Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Lund University to develop treatment for Parkinson's diseases; and bluebird bio, Inc. to develop genome editing treatments for children and adult patients. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.",
    "website": "http://www.novonordisk.com",
    "zipcode": "2880"
  },
  "NOVA.DE": {
    "city": "Bagsvaerd",
    "country": "Denmark",
    "currency": "EUR",
    "exchange": "GER",
    "industry": "Biotechnology",
    "long_name": "Novo Nordisk A/S",
    "market": "de_market",
    "market_cap": "Large Cap",
    "sector": "Healthcare",
    "short_name": "NOVO-NORDISK B ADR/1DK 10",
    "state": null,
    "summary": "Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Lund University to develop treatment for Parkinson's diseases; and bluebird bio, Inc. to develop genome editing treatments for children and adult patients. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.",
    "website": "http://www.novonordisk.com",
    "zipcode": "2880"
  },
  "NOVA.F": {
    "city": "Bagsvaerd",
    "country": "Denmark",
    "currency": "EUR",
    "exchange": "FRA",
    "industry": "Biotechnology",
    "long_name": "Novo Nordisk A/S",
    "market": "dr_market",
    "market_cap": "Large Cap",
    "sector": "Healthcare",
    "short_name": "NOVO-NORDISK B ADR/1DK 10",
    "state": null,
    "summary": "Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Lund University to develop treatment for Parkinson's diseases; and bluebird bio, Inc. to develop genome editing treatments for children and adult patients. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.",
    "website": "http://www.novonordisk.com",
    "zipcode": "2880"
  },
  "NOVC.F": {
    "city": "Bagsvaerd",
    "country": "Denmark",
    "currency": "EUR",
    "exchange": "FRA",
    "industry": "Biotechnology",
    "long_name": "Novo Nordisk A/S",
    "market": "dr_market",
    "market_cap": "Large Cap",
    "sector": "Healthcare",
    "short_name": "NOVO-NORDISK NAM.B DK-,20",
    "state": null,
    "summary": "Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Lund University to develop treatment for Parkinson's diseases; and bluebird bio, Inc. to develop genome editing treatments for children and adult patients. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.",
    "website": "http://www.novonordisk.com",
    "zipcode": "2880"
  },
  "NOVO-B.CO": {
    "city": "Bagsvaerd",
    "country": "Denmark",
    "currency": "DKK",
    "exchange": "CPH",
    "industry": "Biotechnology",
    "long_name": "Novo Nordisk A/S",
    "market": "dk_market",
    "market_cap": "Large Cap",
    "sector": "Healthcare",
    "short_name": "Novo Nordisk B A/S",
    "state": null,
    "summary": "Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Lund University to develop treatment for Parkinson's diseases; and bluebird bio, Inc. to develop genome editing treatments for children and adult patients. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.",
    "website": "http://www.novonordisk.com",
    "zipcode": "2880"
  },
  "NVO": {
    "city": "Bagsvaerd",
    "country": "Denmark",
    "currency": "USD",
    "exchange": "NYQ",
    "industry": "Biotechnology",
    "long_name": "Novo Nordisk A/S",
    "market": "us_market",
    "market_cap": "Large Cap",
    "sector": "Healthcare",
    "short_name": "Novo Nordisk A/S",
    "state": null,
    "summary": "Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Lund University to develop treatment for Parkinson's diseases; and bluebird bio, Inc. to develop genome editing treatments for children and adult patients. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.",
    "website": "http://www.novonordisk.com",
    "zipcode": "2880"
  },
  "NVON.MX": {
    "city": "Bagsvaerd",
    "country": "Denmark",
    "currency": "MXN",
    "exchange": "MEX",
    "industry": "Biotechnology",
    "long_name": "Novo Nordisk A/S",
    "market": "mx_market",
    "market_cap": "Large Cap",
    "sector": "Healthcare",
    "short_name": "NOVO NORDISK A/S",
    "state": null,
    "summary": "Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Lund University to develop treatment for Parkinson's diseases; and bluebird bio, Inc. to develop genome editing treatments for children and adult patients. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.",
    "website": "http://www.novonordisk.com",
    "zipcode": "2880"
  },
  "ORPH": {
    "city": "Copenhagen",
    "country": "Denmark",
    "currency": "USD",
    "exchange": "NMS",
    "industry": "Biotechnology",
    "long_name": "Orphazyme A/S",
    "market": "us_market",
    "market_cap": "Small Cap",
    "sector": "Healthcare",
    "short_name": "Orphazyme A/S",
    "state": null,
    "summary": "Orphazyme A/S, a biopharmaceutical company, develops therapies for the treatment of neurodegenerative orphan diseases. The company focuses on the amplification of heat-shock proteins to develop and commercialize therapeutics for diseases caused by protein misfolding and aggregation, and lysosomal dysfunction, including lysosomal storage and neuromuscular degenerative diseases. Its lead candidate is the Arimoclomol, which is in clinical development for four orphan diseases, including Niemann-Pick disease type C, Amyotrophic Lateral Sclerosis, Inclusion Body Myositis, and Gaucher disease. The company was incorporated in 2009 and is headquartered in Copenhagen, Denmark.",
    "website": "http://www.orphazyme.com",
    "zipcode": "2200"
  },
  "ORPHA.CO": {
    "city": "Copenhagen",
    "country": "Denmark",
    "currency": "DKK",
    "exchange": "CPH",
    "industry": "Biotechnology",
    "long_name": "Orphazyme A/S",
    "market": "dk_market",
    "market_cap": "Micro Cap",
    "sector": "Healthcare",
    "short_name": "Orphazyme A/S",
    "state": null,
    "summary": "Orphazyme A/S, a biopharmaceutical company, develops therapies for the treatment of neurodegenerative orphan diseases. The company focuses on the amplification of heat-shock proteins to develop and commercialize therapeutics for diseases caused by protein misfolding and aggregation, and lysosomal dysfunction, including lysosomal storage and neuromuscular degenerative diseases. Its lead candidate is the Arimoclomol, which is in clinical development for four orphan diseases, including Niemann-Pick disease type C, Amyotrophic Lateral Sclerosis, Inclusion Body Myositis, and Gaucher disease. The company was incorporated in 2009 and is headquartered in Copenhagen, Denmark.",
    "website": "http://www.orphazyme.com",
    "zipcode": "2200"
  },
  "OZYMF": {
    "city": "Copenhagen",
    "country": "Denmark",
    "currency": "USD",
    "exchange": "PNK",
    "industry": "Biotechnology",
    "long_name": "Orphazyme A/S",
    "market": "us_market",
    "market_cap": "Small Cap",
    "sector": "Healthcare",
    "short_name": "ORPHAZYME A/S",
    "state": null,
    "summary": "Orphazyme A/S, a biopharmaceutical company, develops therapies for the treatment of neurodegenerative orphan diseases. The company focuses on the amplification of heat-shock proteins to develop and commercialize therapeutics for diseases caused by protein misfolding and aggregation, and lysosomal dysfunction, including lysosomal storage and neuromuscular degenerative diseases. Its lead candidate is the Arimoclomol, which is in clinical development for four orphan diseases, including Niemann-Pick disease type C, Amyotrophic Lateral Sclerosis, Inclusion Body Myositis, and Gaucher disease. The company was incorporated in 2009 and is headquartered in Copenhagen, Denmark.",
    "website": "http://www.orphazyme.com",
    "zipcode": "2200"
  },
  "SANION.ST": {
    "city": "Glostrup",
    "country": "Denmark",
    "currency": "SEK",
    "exchange": "STO",
    "industry": "Biotechnology",
    "long_name": "Saniona AB (publ)",
    "market": "se_market",
    "market_cap": "Micro Cap",
    "sector": "Healthcare",
    "short_name": "Saniona AB",
    "state": null,
    "summary": "Saniona AB (publ), a research and development company, engages in the development of drugs for diseases of the central nervous system and eating disorders in Denmark. It has a portfolio of various drug candidates in pre-clinical and clinical stages. The company's products include Tesofensine, a triple monoamine reuptake inhibitor; Tesomet, a fix-dose combination of tesofensine and metoprolol that has completed the Phase 2 clinical trials for the treatment of prader-willi syndrome and hypothalamic obesity; and CAD-1883 for movement disorders. It is also developing SAN711 for rare neuropathic disorders, which is in Phase 1; SAN903 that is in preclinical stage for rare inflammatory/fibrotic disorders; and Boehringer Ingelheim program for schizophrenia. Saniona AB (publ) was founded in 2011 and is headquartered in Glostrup, Denmark.",
    "website": "http://www.saniona.com",
    "zipcode": "2600"
  },
  "SCOL.ST": {
    "city": "Copenhagen",
    "country": "Denmark",
    "currency": "SEK",
    "exchange": "STO",
    "industry": "Biotechnology",
    "long_name": "Scandion Oncology A/S",
    "market": "se_market",
    "market_cap": "Micro Cap",
    "sector": "Healthcare",
    "short_name": "Scandion Oncology A/S",
    "state": null,
    "summary": "Scandion Oncology A/S, a biotechnology company, develops drugs for the treatment of chemotherapy resistance in cancer patients. Its products under development include SCO-101, which is in Phase II clinical trial for use in the treatment of breast and colorectal cancers; and SCO-201, a late pre-clinical stage product for use in the treatment of solid tumors. Scandion Oncology A/S has a collaboration agreement with Alligator Bioscience AB to explore combination therapies for chemotherapy and immunooncology. The company was founded in 2017 and is based in Copenhagen, Denmark.",
    "website": "http://www.scandiononcology.com",
    "zipcode": "2100"
  },
  "VIBI": {
    "city": "NÃ¦stved",
    "country": "Denmark",
    "currency": "USD",
    "exchange": "PNK",
    "industry": "Biotechnology",
    "long_name": "Vilacto Bio Inc.",
    "market": "us_market",
    "market_cap": "Nano Cap",
    "sector": "Healthcare",
    "short_name": "VILACTO BIO INC",
    "state": null,
    "summary": "Vilacto Bio Inc. operates as a biotech company in Denmark. The company holds a patented molecule license, known as the Lactoactive molecule for the treatment of inflammatory diseases, diabetics, psoriasis, and skin issues in various levels. It markets a line of skin care products, including lotions, skin care creams and gels, lip balms, foot creams and oils, and other items through its Website, vilacto.com. The company was formerly known as Zlato, Inc. and changed its name to Vilacto Bio Inc. in April 2017. Vilacto Bio Inc. was founded in 2013 and is headquartered in Naestved, Denmark.",
    "website": "http://www.vilacto.com",
    "zipcode": "4700"
  },
  "ZEAL": {
    "city": "Copenhagen",
    "country": "Denmark",
    "currency": "USD",
    "exchange": "NMS",
    "industry": "Biotechnology",
    "long_name": "Zealand Pharma A/S",
    "market": "us_market",
    "market_cap": "Small Cap",
    "sector": "Healthcare",
    "short_name": "Zealand Pharma A/S",
    "state": null,
    "summary": "Zealand Pharma A/S, a biotechnology company, engages in the discovery, design, and development of peptide-based medicines in Denmark. It has a portfolio of medicines focusing on gastrointestinal and metabolic diseases, and other specialty disease areas with unmet medical needs. The company markets lixisenatide under the brand names of Adlyxin, Lyxumia, Soliqua 100/33, and Suliqua. Its product pipeline includes Dasiglucagon single use syringe or autoinjector that has completed Phase III clinical trials for the treatment of severe hypoglycemia; Dasiglucagon dual-hormone artificial pancreas has completed Phase II clinical trials for automated diabetes management; Dasiglucagon that is in Phase III clinical trials for congenital hyperinsulinism and in Phase II clinical trials for post bariatric surgery hypoglycemia. The company is also developing glepaglutide, a long acting GLP-2 analog, which is in Phase III clinical trials for the treatment of short bowel syndrome. Zealand Pharma A/S has collaboration agreements with Sanofi-Aventis Deutschland GmbH; Boehringer Ingelheim International GmbH; Alexion; and Beta Bionics, Inc. The company was founded in 1997 and is headquartered in Copenhagen, Denmark.",
    "website": "http://www.zealandpharma.com",
    "zipcode": "2860"
  },
  "ZEAL.CO": {
    "city": "Copenhagen",
    "country": "Denmark",
    "currency": "DKK",
    "exchange": "CPH",
    "industry": "Biotechnology",
    "long_name": "Zealand Pharma A/S",
    "market": "dk_market",
    "market_cap": "Small Cap",
    "sector": "Healthcare",
    "short_name": "Zealand Pharma A/S",
    "state": null,
    "summary": "Zealand Pharma A/S, a biotechnology company, engages in the discovery, design, and development of peptide-based medicines in Denmark. It has a portfolio of medicines focusing on gastrointestinal and metabolic diseases, and other specialty disease areas with unmet medical needs. The company markets lixisenatide under the brand names of Adlyxin, Lyxumia, Soliqua 100/33, and Suliqua. Its product pipeline includes Dasiglucagon single use syringe or autoinjector that has completed Phase III clinical trials for the treatment of severe hypoglycemia; Dasiglucagon dual-hormone artificial pancreas has completed Phase II clinical trials for automated diabetes management; Dasiglucagon that is in Phase III clinical trials for congenital hyperinsulinism and in Phase II clinical trials for post bariatric surgery hypoglycemia. The company is also developing glepaglutide, a long acting GLP-2 analog, which is in Phase III clinical trials for the treatment of short bowel syndrome. Zealand Pharma A/S has collaboration agreements with Sanofi-Aventis Deutschland GmbH; Boehringer Ingelheim International GmbH; Alexion; and Beta Bionics, Inc. The company was founded in 1997 and is headquartered in Copenhagen, Denmark.",
    "website": "http://www.zealandpharma.com",
    "zipcode": "2860"
  },
  "ZLDPF": {
    "city": "Copenhagen",
    "country": "Denmark",
    "currency": "USD",
    "exchange": "PNK",
    "industry": "Biotechnology",
    "long_name": "Zealand Pharma A/S",
    "market": "us_market",
    "market_cap": "Small Cap",
    "sector": "Healthcare",
    "short_name": "ZEALAND PHARMA AS",
    "state": null,
    "summary": "Zealand Pharma A/S, a biotechnology company, engages in the discovery, design, and development of peptide-based medicines in Denmark. It has a portfolio of medicines focusing on gastrointestinal and metabolic diseases, and other specialty disease areas with unmet medical needs. The company markets lixisenatide under the brand names of Adlyxin, Lyxumia, Soliqua 100/33, and Suliqua. Its product pipeline includes Dasiglucagon single use syringe or autoinjector that has completed Phase III clinical trials for the treatment of severe hypoglycemia; Dasiglucagon dual-hormone artificial pancreas has completed Phase II clinical trials for automated diabetes management; Dasiglucagon that is in Phase III clinical trials for congenital hyperinsulinism and in Phase II clinical trials for post bariatric surgery hypoglycemia. The company is also developing glepaglutide, a long acting GLP-2 analog, which is in Phase III clinical trials for the treatment of short bowel syndrome. Zealand Pharma A/S has collaboration agreements with Sanofi-Aventis Deutschland GmbH; Boehringer Ingelheim International GmbH; Alexion; and Beta Bionics, Inc. The company was founded in 1997 and is headquartered in Copenhagen, Denmark.",
    "website": "http://www.zealandpharma.com",
    "zipcode": "2860"
  }
}
